Related references
Note: Only part of the references are listed.Management of systemic sclerosis-associated interstitial lung disease in the current era
Sogol Sara Amjadi et al.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2020)
Treatment of systemic sclerosis-associated interstitial lung disease: Lessons from clinical trials
David Roofeh et al.
JOURNAL OF SCLERODERMA AND RELATED DISORDERS (2020)
Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology
Dorcas E. Beaton et al.
JOURNAL OF RHEUMATOLOGY (2019)
Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II
Elizabeth R. Volkmann et al.
JOURNAL OF RHEUMATOLOGY (2019)
Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT Methodology
Lara J. Maxwell et al.
JOURNAL OF RHEUMATOLOGY (2019)
OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies
Maarten Boers et al.
JOURNAL OF RHEUMATOLOGY (2019)
Management of systemic sclerosis-associated interstitial lung disease
David Roofeh et al.
CURRENT OPINION IN RHEUMATOLOGY (2019)
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease
Oliver Distler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Systemic Sclerosis Associated Interstitial Lung Disease: A Comprehensive Overview
John A. Mackintosh et al.
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE (2019)
Intraclass correlation - A discussion and demonstration of basic features
David Liljequist et al.
PLOS ONE (2019)
Standardization of Spirometry 2019 Update An Official American Thoracic Society and European Respiratory Society Technical Statement
Brian L. Graham et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2019)
Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts
Elizabeth R. Volkmann et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Interstitial lung disease associated with systemic sclerosis (SSc-ILD)
Vincent Cottin et al.
RESPIRATORY RESEARCH (2019)
Reliability and Minimal Clinically Important Differences of FVC Results from the Scleroderma Lung Studies (SLS-I and SLS-II)
Suzanne Kafaja et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model
Wanlong Wu et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Assessing Mortality Models in Systemic Sclerosis-Related Interstitial Lung Disease
Robert L. Mango et al.
LUNG (2018)
Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma
K. M. Sullivan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Performance of Forced Vital Capacity and Lung Diffusion Cutpoints for Associated Radiographic Interstitial Lung Disease in Systemic Sclerosis
Kimberly Showalter et al.
JOURNAL OF RHEUMATOLOGY (2018)
Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)
Dinesh Khanna et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease
Melissa Caron et al.
EUROPEAN RESPIRATORY REVIEW (2018)
Does Systemic Sclerosis-associated Interstitial Lung Disease Burn Out? Specific Phenotypes of Disease Progression
Sabina A. Guler et al.
ANNALS OF THE AMERICAN THORACIC SOCIETY (2018)
Official ERS technical standards: Global Lung Function Initiative reference values for the carbon monoxide transfer factor for Caucasians
Sanja Stanojevic et al.
EUROPEAN RESPIRATORY JOURNAL (2017)
2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung
Brian L. Graham et al.
EUROPEAN RESPIRATORY JOURNAL (2017)
Interstitial lung disease points to consider for clinical trials in systemic sclerosis
Dinesh Khanna et al.
RHEUMATOLOGY (2017)
A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease
Dimitrios Daoussis et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2017)
Clinical algorithms for the diagnosis and prognosis of interstitial lung disease in systemic sclerosis
Vanessa Hax et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2017)
Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease An Analysis of Scleroderma Lung Studies I and II
Elizabeth R. Volkmann et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis
Nicole S. Goh et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Recommendations for a Standardized Pulmonary Function Report An Official American Thoracic Society Technical Statement
Bruce H. Culver et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2017)
Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease The SADL Model
Julie Morisset et al.
CHEST (2017)
Improved Cough and Cough-Specific Quality of Life in Patients Treated for Scleroderma-Related Interstitial Lung Disease Results of Scleroderma Lung Study II
Donald P. Tashkin et al.
CHEST (2017)
Management of connective tissue diseases associated interstitial lung disease: a review of the published literature
Beth Wallace et al.
CURRENT OPINION IN RHEUMATOLOGY (2016)
Computer-Aided Tomographic Analysis of Interstitial Lung Disease (ILD) in Patients with Systemic Sclerosis (SSc). Correlation with Pulmonary Physiologic Tests and Patient Centred Measures of Perceived Dyspnea and Functional Disability
Fausto Salaffi et al.
PLOS ONE (2016)
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial
Donald P. Tashkin et al.
LANCET RESPIRATORY MEDICINE (2016)
Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis
Donald P. Tashkin et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research
Terry K. Koo et al.
JOURNAL OF CHIROPRACTIC MEDICINE (2016)
Causes and prevalence of inadequate pulmonary function testing among patients with systemic sclerosis
Pichaporn Sumphao-Ngern et al.
ARCHIVES OF MEDICAL SCIENCE (2015)
Predicting Mortality in Systemic Sclerosis-Associated Interstitial Lung Disease Using Risk Prediction Models Derived From Idiopathic Pulmonary Fibrosis
Christopher J. Ryerson et al.
CHEST (2015)
Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) - Report from OMERACT CTD-ILD Working Group
Dinesh Khanna et al.
JOURNAL OF RHEUMATOLOGY (2015)
Predictive Value of Serial High-Resolution Computed Tomography Analyses and Concurrent Lung Function Tests in Systemic Sclerosis
Anna-Maria Hoffmann-Vold et al.
ARTHRITIS & RHEUMATOLOGY (2015)
Pulmonary Function Tests: High Rate of False-Negative Results in the Early Detection and Screening of Scleroderma-Related Interstitial Lung Disease
Yossra A. Suliman et al.
ARTHRITIS & RHEUMATOLOGY (2015)
Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials
Dinesh Khanna et al.
ARTHRITIS RESEARCH & THERAPY (2015)
Predicting Survival Across Chronic Interstitial Lung Disease The ILD-GAP Model
Christopher J. Ryerson et al.
CHEST (2014)
Mortality in systemic sclerosis: lessons learned from population-based and observational cohort studies
Mandana Nikpour et al.
CURRENT OPINION IN RHEUMATOLOGY (2014)
Interstitial lung disease in connective tissue disease-mechanisms and management
Athol U. Wells et al.
NATURE REVIEWS RHEUMATOLOGY (2014)
Interstitial lung disease in systemic sclerosis
Athol U. Wells
PRESSE MEDICALE (2014)
Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study
Paolo Fraticelli et al.
ARTHRITIS RESEARCH & THERAPY (2014)
Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease
Owen A. Moore et al.
RHEUMATOLOGY (2013)
Correlation of Cough With Disease Activity and Treatment With Cyclophosphamide in Scleroderma Interstitial Lung Disease Findings From the Scleroderma Lung Study
Arthur C. Theodore et al.
CHEST (2012)
Predicting Treatment Outcomes and Responder Subsets in Scleroderma-Related Interstitial Lung Disease
Michael D. Roth et al.
ARTHRITIS AND RHEUMATISM (2011)
A One-Year, Phase I/IIa, Open-Label Pilot Trial of Imatinib Mesylate in the Treatment of Systemic Sclerosis-Associated Active Interstitial Lung Disease
Dinesh Khanna et al.
ARTHRITIS AND RHEUMATISM (2011)
A long-term prospective randomized controlled study of non-specific interstitial pneumonia (NSIP) treatment in scleroderma
Diogo S. Domiciano et al.
CLINICAL RHEUMATOLOGY (2011)
Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial
Richard K. Burt et al.
LANCET (2011)
Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database
Anthony J. Tyndall et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort
Shervin Assassi et al.
ARTHRITIS RESEARCH & THERAPY (2010)
Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design
Dinesh Khanna et al.
CURRENT RHEUMATOLOGY REVIEWS (2010)
Treatment of Scleroderma-Interstitial Lung Disease With Cyclophosphamide Is Associated With Less Progressive Fibrosis on Serial Thoracic High-Resolution CT Scan Than Placebo Findings From the Scleroderma Lung Study
Jonathan Goldin et al.
CHEST (2009)
Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial-results from the Scleroderma Lung Study
Dinesh Khanna et al.
RHEUMATOLOGY (2009)
Interstitial lung disease in systemic sclerosis - A simple staging system
Nicole S. L. Goh et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2008)
High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease
Jonathan G. Goldin et al.
CHEST (2008)
Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes
Dennis Revicki et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2008)
The relationship of dyspnoea to function and quality of life in systemic sclerosis
M. Baron et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Effects of 1-year treatment with CycNophosphamilde on outcomes at 2 years in scleroderma lung disease
Donald P. Tashkin et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2007)
Changes in causes of death in systemic sclerosis, 1972-2002
Virginia D. Steen et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma
Rachel K. Hoyles et al.
ARTHRITIS AND RHEUMATISM (2006)
Cyclophosphamide versus placebo in scleroderma lung disease
Donald P. Tashkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Interpretative strategies for lung function tests
R Pellegrino et al.
EUROPEAN RESPIRATORY JOURNAL (2005)
Standardisation of the single-breath determination of carbon monoxide uptake in the lung
N MacIntyre et al.
EUROPEAN RESPIRATORY JOURNAL (2005)
Standardisation of spirometry
MR Miller et al.
EUROPEAN RESPIRATORY JOURNAL (2005)